300 related articles for article (PubMed ID: 30187666)
1. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
Kuo S; Yang CT; Wu JS; Ou HT
Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
[TBL] [Abstract][Full Text] [Related]
2. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
4. Impact of type 2 diabetes on postoperative outcome after hip fracture: nationwide population-based study in Taiwan.
Lee TC; Lee YL; Chen JC; Chen CH; Ho PS
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32086279
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
6. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
7. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
8. Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.
Folse HJ; Mukherjee J; Sheehan JJ; Ward AJ; Pelkey RL; Dinh TA; Qin L; Kim J
Diabetes Obes Metab; 2017 Jul; 19(7):1006-1013. PubMed ID: 28211604
[TBL] [Abstract][Full Text] [Related]
9. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
[TBL] [Abstract][Full Text] [Related]
10. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795
[TBL] [Abstract][Full Text] [Related]
11. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
13. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
[TBL] [Abstract][Full Text] [Related]
14. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
Gautam S; Agiro A; Barron J; Power T; Weisman H; White J
Cardiovasc Diabetol; 2017 Jul; 16(1):93. PubMed ID: 28756774
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the early initiation of insulin treatment and diabetic complications in patients newly diagnosed with type 2 diabetes mellitus in Korea: A nationwide cohort study.
Jeon HL; Kim W; Kim B; Shin JY
J Diabetes Investig; 2022 May; 13(5):830-838. PubMed ID: 34825507
[TBL] [Abstract][Full Text] [Related]
17. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
[TBL] [Abstract][Full Text] [Related]
19. The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression.
Xing S; Calip GS; Leow AD; Kim S; Schumock GT; Touchette DR; Lee TA
J Diabetes Complications; 2018 May; 32(5):492-500. PubMed ID: 29544744
[TBL] [Abstract][Full Text] [Related]
20. Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus.
Machado-Alba JE; Machado-Duque ME; Moreno-Gutierrez PA
Diabetes Res Clin Pract; 2015 Mar; 107(3):332-7. PubMed ID: 25648389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
